arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Neuraxis, INC

NRXS
$6.04 ▼ -0.79 (-11.57%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuraxis, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $73.2M
Dividend Yield —
Revenue Growth 115.7% ↗
Op. Margin -110.2% →
ROIC -24.9% ↘
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book 11.2x
FCF Yield —
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.93M
↑ +115.7% —
Net Income Profit after all expenses
$-1.76M
↑ +22.7% —
Operating Margin Operating profit as % of sales
-110.2%
↓ -1.8% 0th
FCF / Share Free cash flow per share
$-0.08
↑ +24.4% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
1
Financial Health ↓
51
Cash Quality ↑
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters